A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS).
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs NP-001 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Neuraltus Pharmaceuticals
- 03 Apr 2017 Results of a post-hoc analysis assessing the prognostic significance of CRP (n=113), published in the JAMA Neurology
- 04 Apr 2016 Secondary analyses results published in a Neuraltus Pharmaceuticals media release.
- 20 Apr 2015 Results published in a Neuraltus Pharmaceuticals media release and online in the April 2015 issue of Neurology: Neuroimmunology & Neuroinflammation.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History